ArticleNature2020
TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers.
0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 219 citations in OpenAlex.
- The role of IRF5 as an immune regulator.Biochemical Society transactions · 2026Review
- The SLC-ome of membrane transport: from molecular discovery to physiology and clinical applications.Physiological reviews · 2026Review
- The SLC15A4-TASL complex is essential for lupus development in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Solute carrier membrane transporters: emerging targets in CNS disorders.Nature reviews. Drug discovery · 2026Review
- Comparative genomic analysis of pigs differing in survival following African swine fever virus infection.Veterinary research communications · 2026Article
- The Pharmacology of the SLC15A4-TASL Complex, an Emerging Target for the Treatment of Lupus.Pharmacology research & perspectives · 2026Review
- TLR7 in systemic lupus erythematosus: genetics and emerging therapies.Nature reviews. Rheumatology · 2026Review
- Animal Models of Idiopathic Inflammatory Myopathies: Bridging Mechanistic Insights and Clinical Translation.International journal of molecular sciences · 2026Review
- SLC15A4 promotes oral cancer progression by regulating TLR9 and activating the JAK/STAT signaling pathway.Head & face medicine · 2026Article
- Female mice with a Xist deletion in B cells can develop lupus-associated phenotypes.Cell reports · 2026Article
- Heterodimerization with signaling-inert TLR8b converts TLR8a from proviral to antiviral sensor in Ctenopharyngodon idella.Cell communication and signaling : CCS · 2026Article
- Noncanonical IRF3 function mediates STING-dependent pro-inflammatory cytokine production in macrophages.EMBO reports · 2026Article
- Toll-like receptor-mediated innate immune response correlate with the pathogenicity of Eimeria tenella infection in SPF chickens.Parasites & vectors · 2026Article
- Ferroptosis and macrophage polarization: mechanisms, interplay, and implications for medical applications.Cell death discovery · 2026Review
- Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- TLR9-activating cholesterol azetidine derivative-assisted therapeutic vaccines for cancer immunotherapy.Science advances · 2026Article
- Nanostructured branched Y-DNA promotes antitumor immunity through dual activation of cGAS/STING and TLR9.Archives of pharmacal research · 2026Article
- The adaptor protein TASL is required for age-related B cell emergence and lupus-like disease development in mice.PLoS biology · 2026Article
- Sex-Specific Factors Influencing HIV Infection.Immunological reviews · 2026Review
- Exploring potential biomarkers of NETosis-Related genes in spinal cord injury through machine learning and multi-omics analysis.Biochemistry and biophysics reports · 2026Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
22 authors at 3 institutions in 2 countries.
Leonhard X HeinzCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-6921-1493
JangEun LeeBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Utkarsh KapoorCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-9406-3074
Felix KartnigCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0001-8540-2831
Vitaly SedlyarovCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-9872-3535
Konstantinos PapakostasCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Adrian César-RazquinCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Patrick EssletzbichlerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0003-2237-0005
Ulrich GoldmannCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0003-1120-6912
Adrijana StefanovicCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Johannes W BigenzahnCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-5214-4570
Stefania ScorzoniCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Mattia D PizzagalliCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Ariel BensimonCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0003-1862-6987
André C MüllerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
F James KingBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Jun LiBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Enrico GirardiCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0003-3508-2723
M Lamine MbowBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.ORCID http://orcid.org/0000-0002-2760-1442
Charles E WhitehurstBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Manuele RebsamenCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. mrebsamen@cemm.oeaw.ac.at.ORCID http://orcid.org/0000-0001-6172-4211
Giulio Superti-FurgaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. gsuperti@cemm.oeaw.ac.at.ORCID http://orcid.org/0000-0002-0570-1768
Austrian Academy of Sciences · ATBoehringer Ingelheim (United States) · USCeMM Research Center for Molecular Medicine · AT
Funding
Austrian Science Fund FWF F 4711European Research Council 695214
Abstract
Toll-like receptors (TLRs) have a crucial role in the recognition of pathogens and initiation of immune responses
Indexed as
Amino Acid MotifsAnimalsFemaleHumansImmunity, InnateInterferon Regulatory FactorsInterferon Type IIntracellular Signaling Peptides and ProteinsLupus Erythematosus, SystemicLysosomesMaleMembrane Transport ProteinsNerve Tissue ProteinsProtein BindingSignal TransductionToll-Like Receptor 7Interferon Regulatory FactorsInterferon Type IIntracellular Signaling Peptides and ProteinsIRF5 protein, humanMembrane Transport ProteinsNerve Tissue ProteinsSLC15A4 protein, humanTASL protein, humanTLR7 protein, humanTLR8 protein, humanTLR9 protein, humanToll-Like Receptor 7Toll-Like Receptor 8Toll-Like Receptor 9
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.